2 New Malaria Treatments Announced as Drug Resistance Grows

Pharmalittle: We're reading about Trump and patent policies, a new malaria drug, and more

AbbVie is ending a decade-long partnership with Calico Life Sciences, an Alphabet-funded biotech company focused on aging research

Novartis says novel drug could counter malaria resistance

Novartis has reported what looks like another big step forward in the treatment of malaria, as a drug with a novel mechanism hits the mark in phase 3

Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains

Phase 3 results for the Novartis malaria drug “GanLum” show it was comparable to the standard of care and led to cure rates that top the threshold recommended by the World Health Organization. If approved, this new combination drug would become the first novel malaria therapy in more than 25 years. The post Novel Novartis Malaria Drug Shows Promise to Become New Asset Against Resistant Strains appeared first on MedCity News.

2 new malaria treatments announced as drug resistance grows

Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based Novartis has released results for a new experimental drug called GanLum.

Scientists create new anti-malaria drug with ‘very high cure rate’

Experts said they were "very excited" by the findings

Single-dose malaria treatment using four drugs achieves high cure rates in clinical trial

Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose of a treatment that utilizes four widely available malaria drugs, according to a new study presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene (ASTMH).